Shell Asset Management Co. Has $3.13 Million Stock Holdings in DexCom, Inc. $DXCM

Shell Asset Management Co. grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 16.8% during the second quarter, Holdings Channel reports. The firm owned 35,812 shares of the medical device company’s stock after acquiring an additional 5,138 shares during the quarter. Shell Asset Management Co.’s holdings in DexCom were worth $3,126,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Nuveen LLC acquired a new position in shares of DexCom in the 1st quarter valued at about $554,893,000. Jennison Associates LLC raised its stake in DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after buying an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA raised its stake in DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock worth $218,175,000 after buying an additional 2,015,971 shares during the period. Federated Hermes Inc. raised its stake in DexCom by 2,371.4% during the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock worth $136,220,000 after buying an additional 1,914,019 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after buying an additional 1,868,241 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,849 shares of company stock valued at $564,733. Insiders own 0.32% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $66.03 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a 50 day moving average price of $75.38 and a two-hundred day moving average price of $77.80. The firm has a market capitalization of $25.89 billion, a P/E ratio of 45.85, a P/E/G ratio of 1.39 and a beta of 1.47. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Robert W. Baird dropped their price target on DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a research note on Friday, September 26th. Mizuho upped their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Argus assumed coverage on DexCom in a research note on Thursday, August 21st. They set a “buy” rating and a $100.00 price target on the stock. Barclays upped their price target on DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Finally, Oppenheimer downgraded DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $97.42.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.